The National Ethics Committee in Biomedical Research under the Ministry of Health (MoH) approves the clinical trial results of the phase 3 of Nanocovax.

Data for protective efficacy of Nanocovax vaccine are not available

Nanocovax vaccine has met the short-term safety requirement based on the reporting result of the phase 3 mid-term clinical trial. The evaluation of efficacy was carried out among 11,430 volunteers within seven days after receiving the first shot and 5,785 people within seven days after getting the second dose, announced the Ministry of Health on September 19.
A medial worker prepares to inject Nanocovax, the first made-in-Vietnam COVID-19 vaccine, into a volunteer as part of human trials on December 17, 2020 (Photo: VNA)

Human trials of 2nd local COVID-19 vaccine expected in January

The Institute of Vaccines and Medical Biologicals (IVAC), based in central Khanh Hoa province, has proposed the Ministry of Health allow human trials of its COVID-19 vaccine to begin in January, two months ahead of schedule.